EXOZ

eXoZymes is a pre-revenue, development-stage cell-free synthetic-biology platform that, by its own admission in the 10-K, has 'no commercialized products at this time' and produces only 'lab scale quantities.' The single revenue figure in the data is $70.1K from FY2023; FY2024 and FY2025 show no product revenue at all. The headline P/S of 1,018.9x is therefore a meaningless artifact of a trivial, stale revenue number — there is no commercial business to value, only a research program. Operating loss widened 63.8% to -$9.72M and net loss widened 56.3% to -$9.16M, with R&D up 98.4%. This is a company spending faster, not approaching breakeven.

The balance sheet is the disqualifier. Cash fell 68.7% to $3.04M while operating cash burn ran -$6.50M for the year. That is roughly five to six months of runway, and the filing states plainly: 'Currently, we do not have any identified sources of funding.' Grant funding — $17.7M cumulative since inception and historically the lifeblood of operations — is shrinking (R&D's jump was driven partly by 'a reduction in grant funding'), and management warns there is 'no assurance' more grants come. Stockholders' equity collapsed 67.4% to $3.40M and the accumulated deficit deepened to -$21.1M. With only 8.48M shares out and a thin cash position, the near-certain next step is a dilutive equity raise on unfavorable terms — the filing explicitly flags that current stockholders 'will be diluted.'